C-DQ79Lift Biosciences
allogeneic neutrophils, cell therapy, immuno-oncology
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-DQ79
C-DQ79C-DQ79allogeneic neutrophils, cell therapy, immuno-oncology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
LIfT BioSciences presents the view that cancer can be treated more effectively by harnessing the innate immune system, especially neutrophils, and that highly potent donor-derived immune cells may be able to kill tumours, limit spread, and help patients who do not respond well to existing therapies.
SourceLIfT BioSciences states that it is committed to developing what it describes as the world's first cell therapy capable of destroying all solid tumours regardless of strain or mutation, and that it plans to achieve this by bringing to market a first-in-class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), with an initial goal of showing remission in high unmet need solid tumours by 2022, including pancreatic cancer.
SourceLIfT BioSciences states that it is committed to developing what it describes as the world's first off-the-shelf cell therapy capable of destroying all solid tumours regardless of strain or mutation, and that it plans to achieve this by commercializing a first-in-class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), with an initial goal of demonstrating remission in high unmet need solid tumours by 2023, beginning with pancreatic cancer.
SourceNo company mission, belief statement, or theory is visible in the provided snapshot text. The visible content appears to be only the Internet Archive Wayback interface and capture metadata, so no extractable company stance can be confirmed from this snapshot alone.
Source